How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

32,045 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation (...) of Splenic Metabolic Activity With 18FDG-PET in Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02572765 Recruitment Status : Not yet recruiting First Posted : October 9, 2015 Last Update Posted : December 18

2015 Clinical Trials

142. Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension

Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02647034 Recruitment Status : Unknown Verified January 2016 by National Taiwan University Hospital. Recruitment status was: Recruiting First Posted : January 6, 2016 Last

2015 Clinical Trials

143. Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients

Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2015 Clinical Trials

144. Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions

Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02552485 Recruitment Status : Completed First Posted : September 17, 2015 Last Update Posted : December 31, 2015 Sponsor: Universitaire Ziekenhuizen Leuven

2015 Clinical Trials

145. 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension The safety and scientific validity of this study is the responsibility

2015 Clinical Trials

146. Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms (...) x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2015 Clinical Trials

147. Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension. (PubMed)

Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension. To evaluate frequency of migraine, vasospasm (VS), family history (FH) of migraine, and family history of glaucoma (FHG) in different types of glaucoma in relation to age and stage of visual field loss (VFL) at diagnosis.A total of 2170 patients with glaucoma or ocular hypertension (OH) were interviewed by using standardized questions concerning FHG, age at diagnosis, and potential

Full Text available with Trip Pro

2015 Investigative Ophthalmology & Visual Science

148. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. (PubMed)

Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. The objective of this study was to evaluate the efficacy and safety of the lercanidipine/valsartan combination compared with lercanidipine monotherapy in patients with hypertension.Part 1 of this study was the randomized, multicenter, double (...) -blind, parallel group, Phase III, 8-week clinical trial to compare superiority of lercanidipine 10 mg/valsartan 80 mg (L10/V80) and lercanidipine 10 mg/valsartan 160 mg (L10/V160) combinations with lercanidipine 10 mg (L10) monotherapy. At screening, hypertensive patients, whose diastolic blood pressure (DBP) was >90 mm Hg after 4 weeks with L10, were randomized to 3 groups of L10, L10/V80, and L10/V160. The primary end point was the change in the mean sitting DBP from baseline (week 0) after 8

2015 Clinical therapeutics

149. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy The safety and scientific validity of this study is the responsibility

2015 Clinical Trials

150. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy The safety and scientific validity of this study

2015 Clinical Trials

151. A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2015 Clinical Trials

152. Diagnosis, Evaluation and Follow-up of Asymptomatic Microhematuria (AMH) in Adults

benign cause. A positive dipstick does not define AMH, and evaluation should be based solely on findings from microscopic examination of urinary sediment and not on a dipstick reading. A positive dipstick reading merits microscopic examination to confirm or refute the diagnosis of AMH. Expert Opinion 2. The assessment of the asymptomatic microhematuria patient should include a careful history, physical examination, and laboratory examination to rule out benign causes of AMH such as infection (...) up or those with other risk factors for carcinoma in situ (e.g., irritative voiding symptoms, current or past tobacco use, chemical exposures), cytology may be useful. Option (Evidence Strength Grade C) 16. Blue light cystoscopy should not be used in the evaluation of patients with asymptomatic microhematuria. Recommendation (Evidence Strength Grade C) 17. If a patient with a history of persistent asymptomatic microhematuria has two consecutive negative annual urinalyses (one per year for two

2016 American Urological Association

153. Management of Hypertension (HTN) in Primary Care

, herbal remedies, and dietary supplements, some of which may raise blood pressure or interfere with the effectiveness of antihypertensive medications 10. History of alcohol and illicit drug use (especially cocaine and other stimulants) 11. Psychosocial and environmental factors (e.g., family situation, employment status and working conditions, level of comprehension) that may influence hypertension controlOctober 2014 Page 24 of 135 A physical exam should include an evaluation for signs of secondary (...) hypertension or hypertensive organ damage. At a minimum, vital signs should include height, weight, and two or more blood pressure readings to include one in each arm, with the patient seated. All hypertensive patients should have a thorough history and physical examination, but need only a limited number of routine investigations. It is beyond the scope of these guidelines to discuss every detail of the clinical evaluation, but it may be useful to summarize the aims, which are to elicit and document

2014 VA/DoD Clinical Practice Guidelines

154. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Haven, CT; Johns Hopkins University 450 Evidence-Based Medicine [ 146#2 CHEST AUGUST 2014 ] S umma r y o f Reco mmenda tio n s Pha r maco logic Th erapy for Pulmonary Arterial Hypertension in Adults 1. We suggest that the severity of a pulmonary arterial hypertension (PAH) patient’s disease be evaluated in a systematic and consistent manner, using a combination of World Health Organization (WHO) functional class (FC), exercise capacity, echocar- diographic, laboratory and hemodynamic vari- ables (...) that drug therapy be chosen on the basis of a methodical evaluation of disease severity and the risk for further short-term deterioration. Th e optimal method of evaluation has not been studied. Despite variability in clinicians’ approaches, 7 the WHO FC ( Table 2 ) 18 provides a patient-centered means of assessing disease TABLE 2 ] World Health Organization Functional Classi? cation of Patients With Pulmonary Hypertension Classi? cation Class I: Patients with PH but without resulting limitation

2014 American College of Chest Physicians

155. Essential Hypertension

) Associated Conditions • Sleep apnea Rationale for Recommendations Recommendations are organized under headings for: • Diagnosis of hypertension • Initial evaluation of newly diagnosed patient • Treatment of hypertension • Monitoring blood pressure control Diagnosis of Hypertension Performing BP measurement. BP readings need to be performed accurately to provide useful information. BP in the office should be checked after 5 minutes of sitting quietly in a chair, with feet on the floor, and arm supported (...) masked hypertension, resulting in more aggressive medication regimens and improved cardiovascular outcomes. Currently, reimbursement for ABPM by Medicare is covered only for suspected WHC, defined by 3 or more office visit BPs >140/90 mm Hg, at least two documented BPs outside the office 30 kg/m 2 ) • Physical inactivity • Dyslipidemia • Diabetes • Estimated GFR 55 for men, >65 for women) • Family history of premature cardiovascular disease (men 3) drugs are needed, consider referral

2014 University of Michigan Health System

156. Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease: An Official ATS Clinical Practice Guideline

catheterization to de?ne PH. Additional details about the diagnostic performance of Doppler echocardiography and NT-pro-BNP are provided in the online supplement, as are the roles of the history, physical examination, chest imaging, and laboratory and pulmonary function testing in the evaluation of suspected PH. Table 3 provides sample questions that a provider can use to elicit a history of dyspnea, and Figure 2 provides a suggested diagnostic algorithm for PH of SCD. Estimating Mortality Risk in SCD Con (...) when patients who received HU for at least 5 years were compared with those who either did not receive HU or who received HU for less than 5 years (30.4 vs. 51.1%; RR, 0.60; 95% CI, 0.44–0.81). At both 9 and 17 years, there was no signi?cant difference in mortality when patients who received HU for any duration were compared with patients who never received HU, suggesting Figure 2. Proposed algorithm for evaluation of pulmonary hypertension related to sickle cell disease. 6MWD = 6-minute walk

2014 American Thoracic Society

157. Management of Arterial Hypertension

Diagnostic evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . .2167 3.1 Bood pressure measurement . . . . . . . . . . . . . . . . . . .2168 3.1.1 Of?ce or clinic blood pressure . . . . . . . . . . . . . . .2168 3.1.2 Out-of-of?ce blood pressure . . . . . . . . . . . . . . . .2168 3.1.3 White-coat (or isolated of?ce) hypertension and masked (or isolated ambulatory) hypertension . . . . . .2170 3.1.4 Clinical indications for out-of-of?ce blood pressure . .2170 3.1.5 Blood pressure during (...) Reduction study GISSI-AF Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Atrial Fibrillation HbA 1c glycated haemoglobin HBPM home blood pressure monitoring HOPE Heart Outcomes Prevention Evaluation HOT Hypertension Optimal Treatment HRT hormone replacement therapy HT hypertension HYVET HYpertension in the Very Elderly Trial IMT intima-media thickness I-PRESERVE Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART Effect of Potentially Modi?able Risk Factors

2013 European Society of Cardiology

158. Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg (...) and 120 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro

2017 Clinical Trials

159. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. (PubMed)

could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity. We aimed to evaluate the impact of RSD or spironolactone 50 mg/day associated with PVI in reducing systolic blood pressure (BP), AF recurrence, and AF burden in patients with a history of paroxysmal AF and mild CKD.This was a single-center, prospective, longitudinal, randomized, double-blind study. The individuals were randomly divided into two groups (PVI + spironolactone, n = 36, and PVI + RSD, n = 33 (...) Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. Atrial fibrillation (AF) commonly occurs in chronic kidney disease (CKD), occasioning adverse outcomes. Merging pulmonary vein isolation (PVI) and renal sympathetic denervation (RSD) may decrease the recurrence of AF in subjects with CKD and uncontrolled hypertension. We considered that RSD

2018 Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing

160. MKSAP: 53-year-old woman with hypertension and chronic active hepatitis B infection

MKSAP: 53-year-old woman with hypertension and chronic active hepatitis B infection Kidney disease with a tubulointerstitial process MKSAP: 53-year-old woman with hypertension and chronic active hepatitis B infection | | December 8, 2018 0 Shares Test your medicine knowledge with the , in partnership with the . A 53-year-old woman is evaluated during a routine follow-up visit. Medical history is significant for hypertension and chronic active hepatitis B infection. Her hepatitis B infection has (...) : Bicarbonate 21 mEq/L (21 mmol/L) Creatinine 1.2 mg/dL (106.1 µmol/L) (3 years ago: 0.8 mg/dL [70.7 µmol/L]) Glucose 87 mg/dL (4.8 mmol/L) Phosphorus 2.2 mg/dL (0.71 mmol/L) Urinalysis 1+ protein; 2+ glucose; no cells or casts Which of the following is the most likely cause of this patient’s kidney findings? A. Hypertensive nephropathy B. Membranoproliferative glomerulonephritis C. Membranous glomerulopathy D. Tubulointerstitial disease MKSAP Answer and Critique The correct answer is D. Tubulointerstitial

2018 KevinMD blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>